Skip to main content
Clinical Trials/ACTRN12616000741482
ACTRN12616000741482Completed未知

A randomised placebo controlled clinical trial on the efficacy of Caralluma supplement for anxiety and stress in healthy adults over eight weeks

RDC Global0 sites117 target enrollmentStarted: June 6, 2016Last updated:
Conditions

Trial Snapshot

Phase
未知
Status
Completed
Sponsor
RDC Global
Enrollment
117

Study Overview

Brief Summary

No summary available.

Study Design

Study Type
Interventional
Allocation
Randomised controlled trial
Primary Purpose
Treatment
Masking
Blinded (masking used)

Eligibility Criteria

Ages
18 Years to 75 Years (—)
Sex
All

Inclusion Criteria

  • Participants will be included for assessment if they self-report mild-moderate anxiety (BAI >9<30), are not diagnosed with depression or a mood disorder, are otherwise healthy, and have given written informed consent.

Exclusion Criteria

  • Participants will be excluded if they:
  • have a known hypersensitivity to herbal drugs, or nutritional supplements;
  • have been diagnosed with hypertension and are receiving medication;
  • have a medical condition which, in the opinion of the investigator, makes them unsuitable or deemed unhealthy (including a BMI > 30);
  • have currently or have a history of chronic alcohol and/or drug abuse;
  • have participated in any other clinical trial during last 30 days;
  • are currently participating in another clinical trial;
  • have been diagnosed with a mood disorder;
  • have minimal or severe anxiety on the Beck Anxiety Inventory (<10, or > 29);
  • suffered severe PMS with mood or pain that would change during the study;
  • suffered from any neurological disorder;
  • are taking supplements that impact mood or appetite (e.g., St John’s Wort, leptin);
  • are already taking Caralluma.

Investigators

Sponsor
RDC Global

Similar Trials

The Efficacy of Caralluma for Anxiety in... | Clinical Trial